Overview

Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
24 week open-labeled extension study to continue monitoring the same group of patients in the previous MRA230TW phase IIIb trial in order to evaluate the long term efficacy and safety of tocilizumab.
Phase:
Phase 3
Details
Lead Sponsor:
Chugai Pharma Taiwan
Treatments:
Methotrexate